Category Archives: PEGylation Success Stories

FDA approved PEGylated drug

To date, eleven PEGylated proteins, antibody fragments, oligonucleotides, and small molecules have been approved by FDA are on the market, including PEGylated bovine adenosine deaminase: pegademase bovine (Adagen); and PEGylated l-asparaginase: pegaspargase (Oncaspar); PEGylated products of interferon-alpha (IFN-alpha): peginterferon-2b (PegIntron) … Continue reading

Posted in Blogs, PEGylated Products on Market, pegylation, PEGylation Success Stories | Tagged , , , | 1 Comment

FDA Approves Constipation Drug PEGylated Naloxol

FDA has approved AstraZeneca’s Movantik for opioid-induced constipation in adults with chronic non-cancer pain. Movantik (naloxegol), an oral once-a-day treatment originally developed by Nektar Therapeutics, can decrease the constipating effects of opioids. The drug’s safety and effectiveness were established in … Continue reading

Posted in PEG Derivatives, PEGylated Products on Market, PEGylation Success Stories | Tagged , , , , | 2 Comments

PEGylated Hyaluronic Acid Nanoparticle Drug Delivery

A research group from the Republic of Korea developed poly(ethylene glycol)-conjugated hyaluronic acid nanoparticles (PEG-HANPs) with high tumor targetability. Doxorubicin (DOX) was chosen as the model anticancer drug and was effectively encapsulated into the mineralized nanoparticles. “The most effective antitumor … Continue reading

Posted in PEG Derivatives, PEGylation Reagents, PEGylation Success Stories | Tagged , , , | Leave a comment

Fluorescent or Radioactive PEG-like Nanoprobes

Researchers from the Massachusetts General Hospital and Harvard Medical School developed novel “PEG-like Nanoprobes’’ with controllable pharmacokinetics and  tunable fluorescence. The “PEG-like Nanoprobes’’ nanoparticles feature a unique design where a single PEG polymer surrounds a short fluorochrome and radiometal bearing … Continue reading

Posted in PEG Derivatives, PEGylation Reagents, PEGylation Success Stories, PEGylation Tools | Leave a comment

Designer Proteins Trigger Cell Death – a new cancer therapy?

Researchers from University of Washington and the Howard Hughes Medical Institute use an innovative computational design approach coupled with in-vitro-targeted evolution to produce a potent polypeptide inhibitor that triggers apoptosis of virus-infected cancer cells, suppresses tumor growth and extends survival … Continue reading

Posted in PEG Derivatives, PEGylation Reagents, PEGylation Success Stories | Tagged , , , | 1 Comment